Catheter-Directed Bivalirudin for Local Anticoagulation and Clot Dissolution in Children Requiring Mechanical Circulatory Support
Case series published in ASAIO J (2025)
Abstract
Bivalirudin is a direct thrombin inhibitor that inhibits both circulating thrombin and fibrin-bound thrombin, giving it the ability to not only prevent thrombus extension, but also more directly facilitate clot resolution than heparin. Although still not yet the standard of care, bivalirudin has become more frequently used for anticoagulation in patients on mechanical circulatory support. In patients who develop large or critically localized thrombosis, requiring catheter-directed therapy, alteplase remains the drug of choice. Here we describe three cases of children, all of whom were on mechanical circulatory support, who required catheter-directed thrombolysis. In each case, direct bivalirudin delivery through a lysis catheter was associated with rapid resolution of thrombosis. Although study of more patients is needed to truly assess safety and efficacy, this series demonstrates that bivalirudin may be an effective drug for thrombolysis and should be considered in patients who have experienced bleeding or other complications from catheter-directed alteplase infusion.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Three pediatric case series describing catheter-directed delivery of bivalirudin for local thrombolysis in children on mechanical circulatory support, showing rapid clot resolution as an alternative to alteplase.
Por qué esto importa para la hirudoterapia
Este artículo describe a tres niños con soporte circulatorio mecánico que recibieron infusión de bivalirudina dirigida por catéter por trombosis de gran tamaño o de localización crítica, observándose una resolución rápida del trombo en cada caso. Los autores sugieren la bivalirudina como una alternativa potencial cuando la alteplasa dirigida por catéter se complica con sangrado. El resumen identifica a la bivalirudina como un inhibidor directo de la trombina, pero no menciona la hirudina, las sanguijuelas ni la terapia con sanguijuelas, y no puede establecerse una conexión defendible con la hirudoterapia o el secretoma de la sanguijuela a partir de este artículo. Los propios autores señalan que se necesitan más pacientes para evaluar la seguridad y la eficacia, y el estudio no es relevante para el ámbito de la ASH.
Citación
Catheter-Directed Bivalirudin for Local Anticoagulation and Clot Dissolution in Children Requiring Mechanical Circulatory Support.
Chaudhry-Waterman N et al. · ASAIO journal, 2025
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026